Lexicon Pharmaceuticals (LXRX)

Lexicon Pharmaceuticals (LXRX) Stock Price & Analysis


LXRX Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.31 - $3.48
Previous Close$2.37
Average Volume (3M)400.51K
Market Cap
Enterprise Value$352.89M
Total Cash (Recent Filing)$138.36M
Total Debt (Recent Filing)$55.29M
Price to Earnings (P/E)-3.8
May 04, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.62
Shares Outstanding188,725,743
10 Day Avg. Volume418,998
30 Day Avg. Volume400,510
Standard Deviation0.34
Financial Highlights & Ratios
Price to Book (P/B)6.03
Price to Sales (P/S)3149.95
Price to Cash Flow (P/CF)1.30
P/FCF Ratio-4.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.54K
Enterprise Value/Gross Profit2.54K
Enterprise Value/Ebitda-3.57
Price Target Upside26.85% Upside
Rating ConsensusHold
Number of Analyst Covering1



Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Lexicon Pharmaceuticals’s price range in the past 12 months?
Lexicon Pharmaceuticals lowest stock price was $1.31 and its highest was $3.48 in the past 12 months.
    What is Lexicon Pharmaceuticals’s market cap?
    Currently, no data Available
    When is Lexicon Pharmaceuticals’s upcoming earnings report date?
    Lexicon Pharmaceuticals’s upcoming earnings report date is May 04, 2023 which is in 34 days.
      How were Lexicon Pharmaceuticals’s earnings last quarter?
      Lexicon Pharmaceuticals released its earnings results on Mar 02, 2023. The company reported -$0.16 earnings per share for the quarter, missing the consensus estimate of -$0.134 by -$0.026.
        Is Lexicon Pharmaceuticals overvalued?
        According to Wall Street analysts Lexicon Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Lexicon Pharmaceuticals pay dividends?
          Lexicon Pharmaceuticals does not currently pay dividends.
          What is Lexicon Pharmaceuticals’s EPS estimate?
          Lexicon Pharmaceuticals’s EPS estimate is -$0.18.
            How many shares outstanding does Lexicon Pharmaceuticals have?
            Lexicon Pharmaceuticals has 188,725,740 shares outstanding.
              What happened to Lexicon Pharmaceuticals’s price movement after its last earnings report?
              Lexicon Pharmaceuticals reported an EPS of -$0.16 in its last earnings report, missing expectations of -$0.134. Following the earnings report the stock price went up 22.936%.
                Which hedge fund is a major shareholder of Lexicon Pharmaceuticals?
                Among the largest hedge funds holding Lexicon Pharmaceuticals’s share is Fisher Asset Management LLC. It holds Lexicon Pharmaceuticals’s shares valued at 1M.


                  Lexicon Pharmaceuticals Stock Smart Score

                  The Lexicon Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Lexicon Pharmaceuticals

                  Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. It drug candidates include XERMELO, Sotagliflozin, LX2761, and LX9211. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.


                  Top 5 ETFs holding LXRX

                  Market Value
                  Smart Score
                  iShares Core S&P Total U.S. Stock Market ETF
                  Schwab U.S. Broad Market ETF
                  Up to five ETFs with an Outperform Smart Score that hold LXRX. The ETFs are listed according to market value of LXRX within the ETF


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Biohaven Ltd.
                  Atara Biotherapeutics
                  C4 Therapeutics
                  Scholar Rock Holding

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis